ResearcherUniversité Paris CitéActive in the last 2 years
Lorenzo Pilla
Matched on ORCID iD 0000-0002-1067-1356; OpenAlex author ID A5111889495. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 3
- CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
- Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
- Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Last author DOI 10.1016/j.ejca.2023.04.012↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Emmanuel Mitry · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Hans Prenen · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Jean‐Luc Van Laethem · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Karen Paula Geboes · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Yago Pico de Coaña · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Roberto Pazo-Cid · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Aurélien Lambert · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Jaime Feliú · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Philippe Alexandre Cassier · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Teresa Mercade Macarulla · 2 shared papers, 2024–2025 · strength 0.36
- Paper CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcome… DOI 10.1016/j.xcrm.2025.102407↗
- Paper Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma… DOI 10.1016/s1470-2045(24)00263-8↗
- Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.19
- Gregory Lawrence Beatty · 1 shared paper, 2025 · strength 0.19
- Édouard Auclin · 1 shared paper, 2023 · strength 0.14
- Caterina Vivaldi · 1 shared paper, 2023 · strength 0.14
- Anthony Turpin · 1 shared paper, 2023 · strength 0.14
- Volker Kunzmann · 1 shared paper, 2023 · strength 0.14
- Thibault Mazard · 1 shared paper, 2023 · strength 0.14
- Sara Lonardi · 1 shared paper, 2023 · strength 0.14
- Kathrin Heinrich · 1 shared paper, 2023 · strength 0.14
- Alice Boilève · 1 shared paper, 2023 · strength 0.14
- Monica Niger · 1 shared paper, 2023 · strength 0.14
- Julien Taı̈eb · 1 shared paper, 2023 · strength 0.14
- Gerald W. Prager · 1 shared paper, 2023 · strength 0.14
- Christoph Benedikt Westphalen · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.